3 Diesel and Gas Engines Maker, Generic Drug Maker and Electricity Trading Exchange Stocks With a Strong Future Roadmap: Kirloskar Oil Engines, Alembic Pharmaceuticals and Indian Energy Exchange
- November 5, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Kirloskar Oil Engines, Alembic Pharmaceuticals and Indian Energy Exchange: ROE of 11.9% to 36.1% and FY22 to FY26 revenue CAGR of 8.4% to 17.7%. Prices as of 4 Nov 2026.
Quick Answer
The three engine, generic drug and power exchange stocks to watch are Kirloskar Oil Engines, Alembic Pharmaceuticals and Indian Energy Exchange. Their return on equity ranges from 11.9% to 36.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 17.7%. Indian Energy Exchange has the highest return on equity at 36.1%, while Kirloskar Oil Engines has the fastest revenue growth at 17.7% a year. Prices are based on the 4 November 2026 close, and this article is educational, not investment advice.
Engine, generic drug and power exchange stocks give investors a way to track businesses that sit close to everyday demand in India. Kirloskar Oil Engines, Alembic Pharmaceuticals and Indian Energy Exchange cover a diesel and gas engines maker, a generic drug maker and an electricity trading exchange.
This list covers three engine, generic drug and power exchange stocks with complete current figures: Kirloskar Oil Engines, Alembic Pharmaceuticals and Indian Energy Exchange. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Engine, Generic Drug and Power Exchange Stocks?
Engine, generic drug and power exchange stocks are listed companies that make diesel and gas engines, generator sets and pumps, sell generic formulations in India and abroad, and run an electronic platform for trading electricity. Their earnings depend on farm and industrial power needs, drug approvals and power trading volumes.
Engine, Generic Drug and Power Exchange Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Kirloskar Oil Engines | 1,802 | 28,722 | 53.7 | 44.4 | 15.9 | 1.48 |
| Alembic Pharmaceuticals | 906.7 | 14,914 | 21.6 | 35.7 | 11.9 | 0.25 |
| Indian Energy Exchange | 111.27 | 9,051 | 17.8 | 40.1 | 36.1 | 0.01 |
On valuation, Alembic Pharmaceuticals and Indian Energy Exchange trade at a P/E below the industry P/E, while Kirloskar Oil Engines trades above it, which reflects the growth the market already expects. Readers comparing engine, generic drug and power exchange stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in engine, generic drug and power exchange stocks can use the coming numbers to test whether growth is holding.
Why Do Engine, Generic Drug and Power Exchange Stocks Have a Strong Roadmap in India?
Engine, generic drug and power exchange stocks have a strong roadmap in India because rising power needs on farms and in factories, wider generic drug demand and growing electricity trading keep widening the market for these companies.
- Engines. Farms and industry need dependable power.
- Generics. Regulated markets buy dependable supply.
- Power exchange. More electricity gets traded each year.
Why Kirloskar Oil Engines Features Among These Engine, Generic Drug and Power Exchange Stocks
Among the engine, generic drug and power exchange stocks on this list, Kirloskar Oil Engines, based in Pune, makes diesel and gas engines, generator sets, pumps and power solutions for industrial, farm and infrastructure use.
Revenue rose from Rs 4,049 crore in FY22 to Rs 7,772 crore in FY26, a compound annual growth rate of 17.7%. Net profit grew from Rs 171 crore in FY22 to Rs 558 crore in FY26, which works out to a compound annual growth rate of 34.4%.
In the June 2026 quarter, revenue grew 12.1% year on year to Rs 2,015 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 1.48 and a market capitalisation of Rs 28,722 crore. The stock trades at a P/E of 53.7, above the industry P/E of 44.4.
Roadmap: Backup power demand from data centres, telecom and infrastructure, a growing exports business and new alternative-fuel engines give it several tracks for growth. A large service network helps it hold on to customers across product cycles.
What to watch: Watch order intake from data centres and the pace of new product launches in cleaner fuels.
Why Alembic Pharmaceuticals Features Among These Engine, Generic Drug and Power Exchange Stocks
Among the machinery, pharma and market shares on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.
In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%.
Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7.
Roadmap: The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.
What to watch: Follow new approvals in the United States, the pace of complex generic launches and domestic growth.
Why Indian Energy Exchange Features Among These Engine, Generic Drug and Power Exchange Stocks
Among the three companies on this list, Indian Energy Exchange operates India’s leading electronic platform for trading electricity, renewable energy certificates and other energy products, earning a fee on every unit traded.
The company has a return on equity of 36.1%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 9,051 crore. The stock trades at a P/E of 17.8, below the industry P/E of 40.1.
Revenue rose from Rs 484 crore in FY22 to Rs 747 crore in FY26, a compound annual growth rate of 11.4%. Net profit grew from Rs 309 crore in FY22 to Rs 493 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 10.1% year on year to Rs 203 crore, while net profit rose 11.6% to Rs 135 crore.
Roadmap: Growing power demand, wider participation of renewable producers and new market segments such as green and ancillary products support traded volumes. The platform model needs little capital and keeps the balance sheet clean.
What to watch: Track traded volumes, new product launches, market share and regulatory moves on market coupling.
Kirloskar Oil Engines vs Alembic Pharmaceuticals vs Indian Energy Exchange on Key Financials
The table below sets the three engine, generic drug and power exchange stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Kirloskar Oil Engines | 4,049 | 7,772 | 17.7% | 558 | 7.2% |
| Alembic Pharmaceuticals | 5,356 | 7,399 | 8.4% | 671 | 9.1% |
| Indian Energy Exchange | 484 | 747 | 11.4% | 493 | 66.0% |
Indian Energy Exchange posts the highest return on equity in this group at 36.1%. Kirloskar Oil Engines combines the largest FY26 revenue at Rs 7,772 crore with the fastest revenue growth, a 17.7% compound annual rate. A useful habit with engine, generic drug and power exchange stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several diesel engine, generic tablet and electricity trading stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Kirloskar Oil Engines | 1,796 | 2,015 | 12.1% |
| Alembic Pharmaceuticals | 1,717 | 2,165 | 26.1% |
| Indian Energy Exchange | 184 | 203 | 10.1% |
Key Risks to Check Before Investing in Engine, Generic Drug and Power Exchange Stocks
Every theme carries risks that deserve a check before any decision. For these engine, generic drug and power exchange stocks, the main points are: Long-term machinery, pharma and market shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio. Tracking promoter holding and management commentary adds context when you study machinery, pharma and market shares.
- Input costs. Metal and material prices can move margins.
- Component costs. Copper, chips and other inputs can move margins.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter engine, generic drug and power exchange stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Engine, Generic Drug and Power Exchange Stocks
Engine, generic drug and power exchange stocks work best when investors track growth, valuation and return on equity side by side. Kirloskar Oil Engines, Alembic Pharmaceuticals and Indian Energy Exchange each have a clear plan to grow. Based on the 4 November 2026 close, Kirloskar Oil Engines trades at Rs 1,802, Alembic Pharmaceuticals at Rs 906.7 and Indian Energy Exchange at Rs 111.27. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these engine, generic drug and power exchange stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track engine, generic drug and power exchange stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are engine, generic drug and power exchange stocks?
Ans. Engine, generic drug and power exchange stocks are listed companies that make diesel and gas engines, generator sets and pumps, sell generic formulations in India and abroad, and run an electronic platform for trading electricity. Their earnings depend on farm and industrial power needs, drug approvals and power trading volumes. This list looks at three of them, Kirloskar Oil Engines, Alembic Pharmaceuticals and Indian Energy Exchange, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.
Which engine, generic drug and power exchange stocks are covered in this list?
Ans. This list covers Kirloskar Oil Engines, Alembic Pharmaceuticals and Indian Energy Exchange. Based on the 4 November 2026 close, Kirloskar Oil Engines traded at Rs 1,802, Alembic Pharmaceuticals at Rs 906.7 and Indian Energy Exchange at Rs 111.27. Their return on equity ranges from 11.9% to 36.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 17.7%.
Why do engine, generic drug and power exchange stocks have a strong future roadmap in India?
Ans. Engine, generic drug and power exchange stocks have a strong roadmap in India because rising power needs on farms and in factories, wider generic drug demand and growing electricity trading keep widening the market for these companies. The main drivers are as follows. Engines. Farms and industry need dependable power. Generics. Regulated markets buy dependable supply. Power exchange. More electricity gets traded each year. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Kirloskar Oil Engines performed financially?
Ans. Revenue rose from Rs 4,049 crore in FY22 to Rs 7,772 crore in FY26, a compound annual growth rate of 17.7%. Net profit grew from Rs 171 crore in FY22 to Rs 558 crore in FY26, which works out to a compound annual growth rate of 34.4%. In the June 2026 quarter, revenue grew 12.1% year on year to Rs 2,015 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 1.48 and a market capitalisation of Rs 28,722 crore. The stock trades at a P/E of 53.7, above the industry P/E of 44.4. Looking ahead, backup power demand from data centres, telecom and infrastructure, a growing exports business and new alternative-fuel engines give it several tracks for growth. A large service network helps it hold on to customers across product cycles.
How has Alembic Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.
How has Indian Energy Exchange performed financially?
Ans. Revenue rose from Rs 484 crore in FY22 to Rs 747 crore in FY26, a compound annual growth rate of 11.4%. Net profit grew from Rs 309 crore in FY22 to Rs 493 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 10.1% year on year to Rs 203 crore, while net profit rose 11.6% to Rs 135 crore. The company has a return on equity of 36.1%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 9,051 crore. The stock trades at a P/E of 17.8, below the industry P/E of 40.1. Looking ahead, growing power demand, wider participation of renewable producers and new market segments such as green and ancillary products support traded volumes. The platform model needs little capital and keeps the balance sheet clean.
What risks should investors check before buying engine, generic drug and power exchange stocks?
Ans. Investors should check a few risks before buying engine, generic drug and power exchange stocks. Input costs. Metal and material prices can move margins. Component costs. Copper, chips and other inputs can move margins. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of engine, generic drug and power exchange stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
